Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB

Condition:   Tuberculosis, Multidrug-Resistant Interventions:   Drug: Delamanid;   Drug: Levofloxacin;   Drug: Bedaquiline;   Drug: Clofazimine;   Drug: Linezolid;   Combination Product: WHO approved MDR-TB treatment regimens Sponsors:   Boston University;   United States Department of Defense;   Novartis Pharmaceuticals;   Pfizer;   Otsuka Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials